Literature DB >> 13679631

The Fas/Fas ligand system and cancer: immune privilege and apoptosis.

Vikki M Abrahams1, Marijke Kamsteeg, Gil Mor.   

Abstract

The Fas/FasL system has been suggested to play an important role in the establishment of immune privilege status for tumors by inducing Fas-mediated apoptosis in tumor-specific lymphocytes. However, the role of cell-surface expressed FasL in tumor cell protection has recently become controversial. Our laboratory has focused on the study of the role of the Fas/FasL system in the normal tissue remodeling of the female reproductive tract and in immune-privileged organs. Our studies have demonstrated a connection between sex hormones and the regulation of the Fas/FasL pathway in immune and reproductive cells. More recently, we have investigated the resistance of tumor cells to Fas-mediated apoptosis. We have also characterized a new form of FasL, different from the classical membranal form, which is secreted by ovarian cancer cells. In this review we describe the main techniques used in these studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679631     DOI: 10.1385/MB:25:1:19

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  40 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex.

Authors:  A Krueger; I Schmitz; S Baumann; P H Krammer; S Kirchhoff
Journal:  J Biol Chem       Date:  2001-03-05       Impact factor: 5.157

3.  Macrophages, estrogen and the microenvironment of breast cancer.

Authors:  G Mor; W Yue; R J Santen; L Gutierrez; M Eliza; L M Berstein; N Harada; J Wang; J Lysiak; S Diano; F Naftolin
Journal:  J Steroid Biochem Mol Biol       Date:  1998-12       Impact factor: 4.292

4.  FasL:Fas ratio--a prognostic factor in breast carcinomas.

Authors:  T Reimer; C Herrnring; D Koczan; D Richter; B Gerber; D Kabelitz; K Friese; H J Thiesen
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

5.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

6.  Bcl-2 relieves the trans-repressive function of the glucocorticoid receptor and inhibits the activation of CPP32-like cysteine proteases.

Authors:  T Miyashita; U Mami; T Inoue; J C Reed; M Yamada
Journal:  Biochem Biophys Res Commun       Date:  1997-04-28       Impact factor: 3.575

Review 7.  Tumor necrosis factor receptor and Fas signaling mechanisms.

Authors:  D Wallach; E E Varfolomeev; N L Malinin; Y V Goltsev; A V Kovalenko; M P Boldin
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

8.  FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier.

Authors:  I Bechmann; G Mor; J Nilsen; M Eliza; R Nitsch; F Naftolin
Journal:  Glia       Date:  1999-07       Impact factor: 7.452

9.  Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors.

Authors:  H Ben-Hur; P Gurevich; M Huszar; A Ben-Arie; V Berman; Y Tendler; O Zinder; R Tchanishev; S Gershon; G Mor; Y Zaltsman; F Kohen; I Zusman
Journal:  Eur J Gynaecol Oncol       Date:  2000       Impact factor: 0.196

10.  Fas-fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease.

Authors:  G Mor; L S Gutierrez; M Eliza; F Kahyaoglu; A Arici
Journal:  Am J Reprod Immunol       Date:  1998-08       Impact factor: 3.886

View more
  14 in total

1.  Glycyrrhetinic Acid inhibits cell growth and induces apoptosis in ovarian cancer a2780 cells.

Authors:  Venus Haghshenas; Shohreh Fakhari; Sako Mirzaie; Mohammadreza Rahmani; Fariba Farhadifar; Sara Pirzadeh; Ali Jalili
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.

Authors:  Li-Ning Xu; Sheng-Quan Zou; Jian-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

3.  β3 -Adrenoceptor as a potential immuno-suppressor agent in melanoma.

Authors:  Maura Calvani; Gennaro Bruno; Massimo Dal Monte; Romina Nassini; Filippo Fontani; Arianna Casini; Lorenzo Cavallini; Matteo Becatti; Francesca Bianchini; Francesco De Logu; Giulia Forni; Giancarlo la Marca; Lido Calorini; Paola Bagnoli; Paola Chiarugi; Alberto Pupi; Chiara Azzari; Pierangelo Geppetti; Claudio Favre; Luca Filippi
Journal:  Br J Pharmacol       Date:  2019-05-09       Impact factor: 8.739

4.  Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy.

Authors:  Susumu Saigusa; Koji Tanaka; Masaki Ohi; Yuji Toiyama; Hiromi Yasuda; Takahito Kitajima; Yoshinaga Okugawa; Yasuhiro Inoue; Yasuhiko Mohri; Masato Kusunoki
Journal:  Mol Clin Oncol       Date:  2014-09-26

5.  Serum markers of apoptosis decrease with age and cancer stage.

Authors:  Nilay Kavathia; Alka Jain; Jeremy Walston; Brock A Beamer; Neal S Fedarko
Journal:  Aging (Albany NY)       Date:  2009-07-14       Impact factor: 5.682

6.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

7.  Status of FAS and FAS Ligand Gene Polymorphisms in Patients with Breast Cancer in Northeastern IRAN.

Authors:  Seyed Amir Jalali; Fatemeh Homaei Shandiz; Jalil Tavakol Afshari; Maryam Davarpanah Tanha Ghochan; Amin Reza Nikpoor; Mojgan Mohammadi
Journal:  Rep Biochem Mol Biol       Date:  2018-10

8.  Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.

Authors:  Peter Joseph DeMaria; Marijo Bilusic; Deric M Park; Christopher R Heery; Renee N Donahue; Ravi A Madan; Mohammad Hadi Bagheri; Julius Strauss; Victoria Shen; Jennifer L Marté; Seth M Steinberg; Jeffrey Schlom; Mark R Gilbert; James L Gulley
Journal:  Oncologist       Date:  2021-03-09

9.  Glycyrrhetinic Acid Induces Apoptosis in Leukemic HL60 Cells Through Upregulating of CD95/ CD178.

Authors:  Sara Pirzadeh; Shohreh Fakhari; Ali Jalili; Sako Mirzai; Bayazeed Ghaderi; Venous Haghshenas
Journal:  Int J Mol Cell Med       Date:  2014

10.  A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival.

Authors:  Guenter Hofmann; Uwe Langsenlehner; Tanja Langsenlehner; Babak Yazdani-Biuki; Heimo Clar; Armin Gerger; Florentine Fuerst; Hellmut Samonigg; Peter Krippl; Wilfried Renner
Journal:  J Cell Mol Med       Date:  2009-02-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.